Unlocking the self: Can microdosing psychedelics make one feel more authentic?
In a month-long study of 18 Dutch microdosers, microdosing days (and the day after) were associated with higher state authenticity and with increases in the number and satisfaction of daily activities, suggesting that enhanced feelings of authenticity may help explain microdosing's reported wellbeing benefits.
Authors
- Pop, I.
- Dinkelacker, J.
Published
Abstract
Background and aim: In the present study, we focus on the relationship between state authenticity – the experience of being true to oneself in a particular moment – and microdosing – a practice that implies repeatedly ingesting very small doses of psychedelics that do not reach the threshold for perceptual alterations. We propose that microdosing could increase state authenticity through influencing people's mood and the number and satisfaction with daily activities.
Methods
We used self-assessments of state authenticity collected from 18 microdosers in the Netherlands across the period of 1 month for a total of 192 observations.
Results
We found that on the microdosing day and the day thereafter, state authenticity was significantly higher. Furthermore, the number of activities and the satisfaction with them were higher on the day when participants microdosed, while the following day only the number of activities was higher. Both the number or activities and the satisfaction with them were positively related to state authenticity.
Conclusion
We propose that feeling and behaving authentically could have a central role in explaining the positive effects of microdosing on health and wellbeing that are reported by current research.
Research Summary of 'Unlocking the self: Can microdosing psychedelics make one feel more authentic?'
Introduction
Authenticity, defined as the subjective experience of being one's true self, is linked to multiple indicators of wellbeing and is usually conceptualised as both a stable trait and a fluctuating state. The authors distinguish state authenticity (momentary feelings of being genuine and congruent with one's values) from trait authenticity (a more enduring disposition), and note prior qualitative reports that ingesting psychedelics can increase feelings of authenticity. Microdosing—repeatedly taking sub‑perceptual doses of psychedelics such as LSD or psilocybin—is a specific practice that community accounts and qualitative studies suggest may increase authenticity, but quantitative tests of this relationship are lacking. Pop and colleagues set out to make the link between microdosing and state authenticity explicit and to provide a first quantitative test. They hypothesised three related effects: that microdosing days would be associated with higher state authenticity via elevated positive mood (H1), that any effect could persist to a lesser degree on the day after dosing (H2), and that microdosing might support value‑aligned behaviour (more activities and greater satisfaction with them), which in turn would increase state authenticity (H3). To examine these hypotheses they used intensive, prospective self‑report data collected from active microdosers over roughly one month.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topic
- APA Citation
Pop, I., & Dinkelacker, J. (2024). Unlocking the self: Can microdosing psychedelics make one feel more authentic?. Nordic Studies on Alcohol and Drugs, 41(2), 142-155. https://doi.org/10.1177/14550725231175353
References (16)
Papers cited by this study that are also in Blossom
Anderson, T., Petranker, R., Christopher, A. et al. · Harm Reduction Journal (2019)
Andersson, M., Kjellgren, A. · Harm Reduction Journal (2019)
Bershad, A. K., Schepers, S. T., Bremmer, M. P. et al. · Biological Psychiatry (2019)
Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)
Johnstad, P. G. · Nordic Studies on Alcohol and Drugs (2018)
Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)
Kometer, M., Schmidt, A., Bachmann, R. et al. · Biological Psychiatry (2012)
Kuypers, K. P. C., Erritzoe, D., Knudsen, G. M. et al. · Journal of Psychopharmacology (2019)
Ona, G., Bouso, J. C. · Neuroscience and Biobehavioral Reviews (2020)
Polito, V., Stevenson, R. J. · PLOS ONE (2019)
Show all 16 referencesShow fewer
Pop, I., Dinkelacker, J. · Journal of Psychedelic Studies (2023)
Prochazkova, L., van Elk, M., Marschall, J. et al. · Neuropsychopharmacology (2025)
Rootman, J. M., Kryskow, P., Harvey, K. et al. · Scientific Reports (2021)
Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)
Smigielski, L., Scheidegger, M., Kometer, M. et al. · NeuroImage (2019)
Webb, M., Copes, H., Hendricks, P. S. · International Journal of Drug Policy (2019)
Cited By (1)
Papers in Blossom that reference this study
Dinkelacker, J., Pop, I. · Journal of Clinical Psychiatry (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.